JP2021504445A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504445A5 JP2021504445A5 JP2020545062A JP2020545062A JP2021504445A5 JP 2021504445 A5 JP2021504445 A5 JP 2021504445A5 JP 2020545062 A JP2020545062 A JP 2020545062A JP 2020545062 A JP2020545062 A JP 2020545062A JP 2021504445 A5 JP2021504445 A5 JP 2021504445A5
- Authority
- JP
- Japan
- Prior art keywords
- ebv
- rna
- vaccine
- antibody titer
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 claims 20
- 229920002477 rna polymer Polymers 0.000 claims 19
- 230000003472 neutralizing effect Effects 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 238000000034 method Methods 0.000 claims 13
- 108700026244 Open Reading Frames Proteins 0.000 claims 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims 8
- 230000028993 immune response Effects 0.000 claims 8
- 150000002632 lipids Chemical class 0.000 claims 4
- 101150059079 EBNA1 gene Proteins 0.000 claims 2
- 101150034762 EBNA3 gene Proteins 0.000 claims 2
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims 2
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims 2
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims 1
- UVBYMVOUBXYSFV-UHFFFAOYSA-N 1-methylpseudouridine Natural products O=C1NC(=O)N(C)C=C1C1C(O)C(O)C(CO)O1 UVBYMVOUBXYSFV-UHFFFAOYSA-N 0.000 claims 1
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 1
- 108020003589 5' Untranslated Regions Proteins 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 101710170470 Glycoprotein 42 Proteins 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 102000002067 Protein Subunits Human genes 0.000 claims 1
- 108010001267 Protein Subunits Proteins 0.000 claims 1
- 108091081024 Start codon Proteins 0.000 claims 1
- 229930182558 Sterol Natural products 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 150000003432 sterols Chemical class 0.000 claims 1
- 235000003702 sterols Nutrition 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023150317A JP2023171398A (ja) | 2017-11-21 | 2023-09-15 | エプスタイン－バーウイルスワクチン |
| JP2025025162A JP2025084808A (ja) | 2017-11-21 | 2025-02-19 | エプスタイン－バーウイルスワクチン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589170P | 2017-11-21 | 2017-11-21 | |
| US62/589,170 | 2017-11-21 | ||
| PCT/US2018/061926 WO2019103993A1 (en) | 2017-11-21 | 2018-11-20 | Epstein-barr virus vaccines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023150317A Division JP2023171398A (ja) | 2017-11-21 | 2023-09-15 | エプスタイン－バーウイルスワクチン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021504445A JP2021504445A (ja) | 2021-02-15 |
| JP2021504445A5 true JP2021504445A5 (enExample) | 2022-01-11 |
Family
ID=66630797
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545062A Pending JP2021504445A (ja) | 2017-11-21 | 2018-11-20 | エプスタイン−バーウイルスワクチン |
| JP2023150317A Pending JP2023171398A (ja) | 2017-11-21 | 2023-09-15 | エプスタイン－バーウイルスワクチン |
| JP2025025162A Pending JP2025084808A (ja) | 2017-11-21 | 2025-02-19 | エプスタイン－バーウイルスワクチン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023150317A Pending JP2023171398A (ja) | 2017-11-21 | 2023-09-15 | エプスタイン－バーウイルスワクチン |
| JP2025025162A Pending JP2025084808A (ja) | 2017-11-21 | 2025-02-19 | エプスタイン－バーウイルスワクチン |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20200282047A1 (enExample) |
| EP (1) | EP3713601A4 (enExample) |
| JP (3) | JP2021504445A (enExample) |
| AU (1) | AU2018372922A1 (enExample) |
| CA (1) | CA3083102A1 (enExample) |
| MA (1) | MA50813A (enExample) |
| WO (1) | WO2019103993A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK4023249T3 (da) | 2014-04-23 | 2025-01-13 | Modernatx Inc | Nukleinsyrevacciner |
| EP4218805A1 (en) | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Infectious disease vaccines |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| US12150980B2 (en) | 2015-07-30 | 2024-11-26 | Modernatx, Inc. | Concatemeric peptide epitope RNAs |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| MA46316A (fr) | 2015-10-22 | 2021-03-24 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| CN117731769A (zh) | 2015-10-22 | 2024-03-22 | 摩登纳特斯有限公司 | 用于水痘带状疱疹病毒(vzv)的核酸疫苗 |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| MA52645B1 (fr) | 2015-10-22 | 2022-06-30 | Modernatx Inc | Vaccins contre le virus respiratoire |
| MD3386484T2 (ro) | 2015-12-10 | 2022-11-30 | Modernatx Inc | Compoziții și metode de livrare a unor agenți terapeutici |
| WO2017201342A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
| CN109937253B (zh) | 2016-09-14 | 2023-06-30 | 摩登纳特斯有限公司 | 高纯度rna组合物及其制备方法 |
| WO2018075980A1 (en) | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US10925958B2 (en) | 2016-11-11 | 2021-02-23 | Modernatx, Inc. | Influenza vaccine |
| MA50335A (fr) | 2016-12-08 | 2020-08-19 | Modernatx Inc | Vaccins à acide nucléique contre des virus respiratoires |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Respiratory syncytial virus vaccine |
| US20200030432A1 (en) | 2017-03-17 | 2020-01-30 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| EP3607074A4 (en) | 2017-04-05 | 2021-07-07 | Modernatx, Inc. | REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| US11912982B2 (en) | 2017-08-18 | 2024-02-27 | Modernatx, Inc. | Methods for HPLC analysis |
| US11866696B2 (en) | 2017-08-18 | 2024-01-09 | Modernatx, Inc. | Analytical HPLC methods |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| MA50253A (fr) | 2017-09-14 | 2020-07-22 | Modernatx Inc | Vaccins à arn contre le virus zika |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| US11395851B2 (en) * | 2018-02-16 | 2022-07-26 | The Wistar Institute Of Anatomy And Biology | Epstein-Barr virus nucleic acid constructs and vaccines made therefrom, and methods of using same |
| EP3773708A2 (en) * | 2018-04-03 | 2021-02-17 | Sanofi | Antigenic epstein barr virus polypeptides |
| JP2021519596A (ja) | 2018-04-03 | 2021-08-12 | サノフイＳａｎｏｆｉ | フェリチンタンパク質 |
| JP2021519599A (ja) | 2018-04-03 | 2021-08-12 | サノフイＳａｎｏｆｉ | 抗原性ｏｓｐａポリペプチド |
| CN112512567A (zh) | 2018-04-03 | 2021-03-16 | 赛诺菲 | 抗原性呼吸道合胞病毒多肽 |
| CA3113025A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| EP4509118A3 (en) | 2018-09-19 | 2025-05-14 | ModernaTX, Inc. | High-purity peg lipids and uses thereof |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| JP2022521094A (ja) | 2019-02-20 | 2022-04-05 | モデルナティエックス インコーポレイテッド | 共転写キャッピング用ｒｎａポリメラーゼバリアント |
| EP3938507A4 (en) | 2019-03-11 | 2023-02-22 | ModernaTX, Inc. | PROCEDURE FOR IN VITRO FED BATCH TRANSCRIPTION |
| MA55321A (fr) | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
| CN110922488A (zh) * | 2019-11-08 | 2020-03-27 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种含EB病毒gp350的自组装纳米颗粒及制备方法和应用 |
| CN111154803B (zh) * | 2020-01-10 | 2022-07-22 | 新乡医学院 | 一种重组EBV gHgL免疫原的制备方法及其应用 |
| JP2023522249A (ja) | 2020-04-22 | 2023-05-29 | ビオンテック・ソシエタス・エウロパエア | コロナウイルスワクチン |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US20240325539A1 (en) | 2020-10-20 | 2024-10-03 | The Chancellor, Masters And Scholars Of The University Of Oxford | Methods and compositions for treating epstein barr virus-associated cancer |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| CN113144187B (zh) * | 2021-01-28 | 2024-03-22 | 安徽智飞龙科马生物制药有限公司 | 一种含EB病毒gHgLgp42蛋白的自组装纳米颗粒及其制备方法与应用 |
| JP2024514183A (ja) * | 2021-04-13 | 2024-03-28 | モデルナティエックス インコーポレイテッド | エプスタイン－バーウイルスｍＲＮＡワクチン |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| EP4658306A1 (en) * | 2023-01-30 | 2025-12-10 | ModernaTX, Inc. | Epstein-barr virus mrna vaccines |
| WO2025229572A1 (en) * | 2024-05-01 | 2025-11-06 | Glaxosmithkline Biologicals Sa | Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004035227A1 (de) * | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
| JP4824389B2 (ja) * | 2005-10-28 | 2011-11-30 | 株式会社医学生物学研究所 | エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途 |
| CN105792842B (zh) * | 2013-10-11 | 2020-06-02 | 美利坚合众国, 由健康及人类服务部部长代表 | 埃巴病毒疫苗 |
| DK4023249T3 (da) * | 2014-04-23 | 2025-01-13 | Modernatx Inc | Nukleinsyrevacciner |
| AU2016342376A1 (en) * | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Sexually transmitted disease vaccines |
| CN117731769A (zh) * | 2015-10-22 | 2024-03-22 | 摩登纳特斯有限公司 | 用于水痘带状疱疹病毒(vzv)的核酸疫苗 |
| MA46316A (fr) * | 2015-10-22 | 2021-03-24 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| CN114404581A (zh) * | 2015-10-22 | 2022-04-29 | 摩登纳特斯有限公司 | 癌症疫苗 |
-
2018
- 2018-11-20 EP EP18881012.1A patent/EP3713601A4/en active Pending
- 2018-11-20 JP JP2020545062A patent/JP2021504445A/ja active Pending
- 2018-11-20 AU AU2018372922A patent/AU2018372922A1/en not_active Abandoned
- 2018-11-20 US US16/765,285 patent/US20200282047A1/en not_active Abandoned
- 2018-11-20 CA CA3083102A patent/CA3083102A1/en active Pending
- 2018-11-20 WO PCT/US2018/061926 patent/WO2019103993A1/en not_active Ceased
- 2018-11-20 MA MA050813A patent/MA50813A/fr unknown
-
2023
- 2023-09-15 JP JP2023150317A patent/JP2023171398A/ja active Pending
-
2025
- 2025-02-19 JP JP2025025162A patent/JP2025084808A/ja active Pending
- 2025-03-19 US US19/084,092 patent/US20250312442A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021504445A5 (enExample) | ||
| CN114081943B (zh) | 一种水痘-带状疱疹mRNA疫苗组合物及其制备方法和应用 | |
| Meyer et al. | Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease | |
| JP2019535665A5 (enExample) | ||
| Sun et al. | Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2 | |
| Toledo et al. | A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers | |
| JP2018531996A5 (enExample) | ||
| Ebensen et al. | The combination vaccine adjuvant system alum/c-di-AMP results in quantitative and qualitative enhanced immune responses post immunization | |
| JP2019501208A5 (enExample) | ||
| Zhou et al. | Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates | |
| Kim et al. | Vaccination with lentiviral vector expressing the nfa1 gene confers a protective immune response to mice infected with Naegleria fowleri | |
| Jiang et al. | CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides | |
| US10596248B2 (en) | Immunomodulating composition for treatment | |
| Velasquez et al. | An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles | |
| Verma et al. | Norovirus (NoV) specific protective immune responses induced by recombinant P dimer vaccine are enhanced by the mucosal adjuvant FlaB | |
| Wu et al. | A potential bivalent mRNA vaccine candidate protects against both RSV and SARS-CoV-2 infections | |
| Liu et al. | A nucleoside-modified mRNA vaccine forming rabies virus-like particle elicits strong cellular and humoral immune responses against rabies virus infection in mice | |
| US8282936B2 (en) | Human papillomavirus vaccine for oral administration | |
| CN119454924A (zh) | 一种高致病性猪繁殖与呼吸综合征病毒mRNA疫苗组合物及其应用 | |
| CN112662695B (zh) | 一种细菌生物膜囊泡bbv作为疫苗载体的构建方法和应用 | |
| Bellier et al. | A thermostable oral SARS-CoV-2 vaccine induces mucosal and protective immunity | |
| Hendricks et al. | Computationally designed mRNA-launched protein nanoparticle vaccines | |
| Fragoso-Saavedra et al. | Induction of mucosal immunity against pathogens by using recombinant baculoviral vectors: Mechanisms, advantages, and limitations | |
| Yin et al. | Hepatitis B virus core particles displaying Mycobacterium tuberculosis antigen ESAT-6 enhance ESAT-6-specific immune responses | |
| Chai et al. | Improved mRNA-based RSV vaccine with PreF forming enveloped virus-like particles |